https://www.live-feeds.com/feed/lilly-raises-diabetes-weight-loss-bar-with-amylin-zepbound-comboContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/lilly-raises-diabetes-weight-loss-bar-with-amylin-zepbound-combohttps://www.live-feeds.com/feed/lilly-raises-diabetes-weight-loss-bar-with-amylin-zepbound-combo#u96570Sat, 03 Oct 2026 11:20:19 +0000Eli Lilly reported mid-stage trial results for EloraTZP, a combination of the amylin asset eloralintide and the approved obesity drug Zepbound. In adults with obesity and type 2 diabetes, the regimen delivered a weight loss of 23.3 percent compared to 14.8 percent for tirzepatide alone. The therapy also achieved greater A1C reduction than tirzepatide 15 mg. The combination swept primary and secondary endpoints in the Phase 2 trial. However, the higher reduction in weight came with an increased rate of treatment discontinuation due to gastrointestinal side effects. Eli Lilly plans to launch a P